Oppenheimer analyst Jay Olson maintained a Buy rating on Karuna Therapeutics (NASDAQ:KRTX) Inc on Monday, setting a price target of $125, which is approximately 33.18% above the present share price of $93.86.
Olson expects Karuna Therapeutics Inc to post earnings per share (EPS) of -$0.33 for the second quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Karuna Therapeutics, with an average price target of $125.17.
The analysts price targets range from a high of $140 to a low of $116.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$10.06 million. The company's market cap is $2.45 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 39.22% success rate.
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.